The California-based drug development company FAScinate Therapeutics, Inc. announced positive results from the first part of a Phase 2 trial of KM-819, a compound
being tested for the treatment of Parkinson’s disease.
The FDA announced that it will lift the full Clinical Hold on IkT-148009, a c-Abl tyrosine kinase inhibitor that has shown promising results at stopping the progression of Parkinson’s disease in animal models.
Ambroxol, the active ingredient in cough syrup, is set to enter a Phase 3 clinical trial early this year in patients with Parkinson’s disease.
Previous research has demonstrated that mutations in the SCNA gene, a gene responsible for the production of alpha-synuclein, are associated with an aggressive form of Parkinson’s disease.
Previous estimates of the incidence of Parkinson’s disease have varied for reasons that are not completely understood but may be attributable to the location of the study, small sample sizes, or how cases were defined.
1ST Biotherapeutics, Inc., announced positive results from a Phase 1 trial of FB-101, an investigational compound being studied to treat Parkinson’s disease and other neurodegenerative disorders.
New research published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association last month demonstrated that patients show declines in cognition, grip strength, and overall health up to several years before being diagnosed with a neurodegenerative disorder.
Based on previous work demonstrating the positive effects of exercise on symptoms of Parkinson’s disease, researchers looked at how irisin, a hormone released during exercise, affected the accumulation of misfolded alpha-synuclein in a mouse model of Parkinson’s.
Seelos Therapeutics announced it has received a grant from the Michael J. Fox Foundation for Parkinson’s Research to continue to research its gene-editing therapy, SLS-004, as a potential treatment for Parkinson’s disease.
New research presented at the European Academy of Neurology (EAN) 2022 Congress has revealed a potential link between specific gene mutations and the rate at which Parkinson’s disease progresses.